Drugs / Mylanta
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06241183 Comparator | Nov 2023 → Dec 2027 expected | dyspepsia, gastroesophageal reflux disease | Stony Brook University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mylanta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06241183 ↗ |
| Route | Oral | “30 ml of oral Maalox/ Mylanta” NCT06241183 ↗ |